At Acadia, we are dedicated to developing innovative medicines for central nervous system (CNS) disorders, and are committed to partnerships and collaborations to expand our pipeline and commercial opportunities. Core tenets of our evaluation process include a focus on differentiated science and novel products candidates in areas with significant unmet need.
The partnerships that we seek include targets within our strategic focus areas of CNS disorders (Neurology and Psychiatry), and genetic diseases. We are interested in opportunities from pre-clinical through Phase 3 programs to commercial-stage products. Our proven capabilities in developing and commercializing the first FDA-approved treatment for Parkinson’s Disease Psychosis provides us with the expertise and capabilities to partner successfully through all stages of the clinical and commercial life-cycle.
We welcome the opportunity to learn more about how we can work together. To further explore partnering opportunities with Acadia, please contact us.
Acadia and Neuren Pharmaceuticals Limited have an exclusive North American License Agreement for the development and commercialization of trofinetide for Rett syndrome and other indications. Rett syndrome is a debilitating neurological disorder that occurs primarily in females following apparently normal development for the first six months of life.
Acadia and Stoke Therapeutics have a collaboration to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system (CNS). The collaboration includes SYNGAP1, MECP2 (Rett syndrome), and an undisclosed CNS target of mutual interest.
Acadia and Vanderbilt University have an exclusive worldwide license agreement to develop and commercialize novel drug candidates targeting the muscarinic M1 receptor with the potential to treat a range of CNS disorders. The collaboration is focused on positive allosteric modulators (PAMs) of the M1 receptor. Highly selective PAMs of the M1 subtype of the muscarinic acetylcholine receptor may represent a novel approach for improving cognitive function and other neuropsychiatric symptoms in patients suffering from CNS disorders.